Original Article
Expression level of serum miRNA-22 and its clinical significance in patients with lung cancer
Yang Xia, Zhang Qiuhong, Su Wenmei, Zhang Ming, Shan Hu, Zhang Jie, Chen Guoan, Guo Chunfang, Li Yali
Published 2019-09-20
Cite as Int J Respir, 2019,39(18): 1373-1378. DOI: 10.3760/cma.j.issn.1673-436X.2019.18.003
Abstract
ObjectiveTo investigate the expression of miRNA-22(miR-22) in serum of patients with lung cancer and its value in the diagnosis of lung cancer.
MethodsSerum samples were collected from total 116 non-small cell lung cancer (NSCLC) cases, 10 small cell lung cancer (SCLC) cases and 152 cancer-free controls.The expression of serum miR-22 was evaluated in all the samples by quantitative real time RT-PCR.Receiver operating characteristic curve (ROC) analysis was used to evaluate the impact of miR-22 on its diagnostic value for lung cancer.
ResultsThe relative expressions of serum miR-22 in NSCLC patients, SCLC patients and cancer-free controls were 1.63±1.43, 1.10±1.64 and -0.02±1.31, respectively.The expression of miR-22 in NSCLC patients was higher than that in SCLC patients and cancer-free controls (F=49.35, P<0.01). while no significant difference was observed between SCLC and cancer-free controls (P>0.05). Moreover, the expressions of miR-22 in patients with stage Ⅰ, Ⅱ and Ⅲ/Ⅳ NSCLC were 1.65±1.36, 1.49±1.60 and 1.00±1.42 respectively and they were all higher than cancer-free controls (all P<0.05). No significant difference of miR-22 expression was found among Ⅰ-Ⅳ stages of NSCLC(all P>0.05). There was no significant difference of miR-22 expression among different pathological subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell lung cancer(all P>0.05). ROC analyses were performed using cancer-free group as negative control and the area under curve values of serum miR-22 were ranged between 0.72-0.82 in either NSCLC group, or its histological subtypes or different stages.When optimal cut-offs were selected the sensitivities and specificities were 70.59%-75.32% and 54.61%-73.03% respectively.
ConclusionsThese data indicated serum miR-22 is of great significance for early diagnosis of lung cancer.As a non-invasive detection method, microRNA-22 is expected to become a new indicator for early diagnosis of lung cancer.
Key words:
Carcinoma, non-small-cell lung; Tumor makers, biological; Early diagnosis; miR-22
Contributor Information
Yang Xia
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710004, China
Zhang Qiuhong
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710004, China
Su Wenmei
Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
Zhang Ming
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710004, China
Shan Hu
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710004, China
Zhang Jie
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710004, China
Chen Guoan
School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China
Guo Chunfang
Department of Thoracic Surgery University of Michigan, Ann Arbor 48109, America
Li Yali
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Xi′an Jiao Tong University, Xi′an 710004, China
